Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Sichuan Biokin Pharmaceutical Co. Ltd. A (SSE:688506), currently being evaluated. In 2025, Sichuan Biokin Pharmaceutical Co. Ltd. A generated $2.52 Billion in revenue and -$1.06 Billion in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Sichuan Biokin Pharmaceutical Co. Ltd. A is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $2.52 Billion
- Free Cash Flow (2025): -$1.06 Billion
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.